中国医药：克拉霉素片通过仿制药一致性评价

Core Viewpoint - China Medical (600056.SH) announced that its wholly-owned subsidiary Tianfang Pharmaceutical (600253) has received approval from the National Medical Products Administration for the supplemental application of Clarithromycin Tablets, which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The approval signifies a regulatory milestone for Tianfang Pharmaceutical, enhancing its product portfolio [1] - Clarithromycin Tablets are now positioned to compete in the market following the successful evaluation [1] - This development may lead to increased revenue opportunities for the company as it expands its offerings in the pharmaceutical sector [1]